CAY10499: Inhibitor of Human Hormone Sensitive Lipase

Lipid remodeling is increasingly recognized as a functional driver of immune-cell state, tumor progression, adipose biology, and vascular disease. A practical way to test this relationship is to perturb defined lipase activities while measuring substrate turnover, lipid mediators, inflammatory phenotypes, and cell viability in parallel. For consistent reagent identity, APExBIO supplies CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, as crystalline small molecule SKU B7841.

CAY10499 is especially useful when an experiment needs a pharmacological handle on human HSL and MGL rather than a broad metabolic stressor. The product information reports an IC50 of 90 nM against recombinant human HSL, 0.5 ± 0.03 μM for MGL-mediated hydrolysis of 4-nitrophenyl acetate, and 76 nM for inhibition of recombinant FAAH-mediated [3H]-arachidonoyl ethanolamide hydrolysis. These values are assay-specific benchmarks, not universal cellular dose predictions, but they provide a rational starting point for assay design.

Setup and principle: placing CAY10499 in a lipid workflow

HSL hydrolyzes triacylglycerols, diacylglycerols, monoacylglycerols, and cholesterol esters. Because these reactions mobilize fatty acids and release esterified cholesterol, HSL perturbation can inform studies of energy availability, steroidogenic lipid supply, foam-cell formation, and adipose-tissue lipolysis. This makes CAY10499 an inhibitor for steroidogenesis research and an enzyme inhibitor for fatty acid mobilization studies, provided that the experiment measures the relevant lipid flux rather than assuming a phenotype from inhibitor exposure alone.

MGL has a distinct experimental value: it regulates the turnover of the endocannabinoid 2-arachidonoylglycerol, or 2-AG. CAY10499 can therefore serve as an MGL inhibitor for lipid metabolism research, while the reported FAAH activity means that anandamide turnover should also be considered when interpreting cellular results. Minimal displacement of [3H]-CP-55940 binding to CB1 and CB2 cannabinoid receptors supports a useful distinction between direct receptor binding and enzyme-level perturbation, although receptor binding and enzyme selectivity should still be tested in the specific model.

As a lipid metabolism assay reagent, CAY10499 is best used in a tiered design: first establish activity in a purified enzyme assay, then confirm lipid changes in cells, and finally connect those changes to a functional phenotype. This sequence helps separate target engagement from secondary consequences such as toxicity, altered differentiation, or solvent effects.

Key Innovation from the Reference Study

The reference study on EV-transferred ATP-citrate lyase in hepatocellular carcinoma identifies a metabolic route by which tumor-derived extracellular vesicles reprogram monocytes toward immunosuppressive tumor-associated macrophages. The reported mechanism centers on EV delivery of ACLY, increased palmitate biosynthesis in recipient monocytes, and enhanced S-palmitoylation and stability of immune checkpoint proteins. The investigators also used CD81-decorated liposomal vesicles to reproduce monocyte targeting and compared ACLY-containing vesicles with vesicles carrying the ACLY inhibitor SB204990.

This finding creates a clear assay opportunity for CAY10499, but not a claim that CAY10499 inhibits ACLY. ACLY is upstream of the lipase activities targeted by CAY10499. A useful experimental choice is therefore to place CAY10499 in a parallel arm that asks whether HSL, MGL, or FAAH-regulated lipid handling contributes to the phenotype generated by EV or liposomal-vesicle exposure. Measure lipid mediators and free fatty acids alongside palmitate production, checkpoint abundance, macrophage markers, and viability. If CAY10499 changes the phenotype while ACLY inhibition produces a different pattern, the result may help distinguish upstream lipogenesis from downstream lipid mobilization.

The article CAY10499: Precision Inhibitor of Human Hormone Sensitive Lipase complements this reference study by explaining the compound as a defined lipase perturbation rather than an ACLY-directed intervention. The related CAY10499 lipid-assay resource extends that concept into chromogenic and cell-based workflows, making it useful when translating the EV-TAM model into measurable enzyme and lipid-flux endpoints.

Step-by-step workflow and protocol enhancements

1. Prepare a controlled stock

CAY10499 is insoluble in water but soluble in DMSO at ≥32.4 mg/mL and in ethanol at ≥8.93 mg/mL. A 10 mM DMSO stock requires 3.553 mg/mL, comfortably below the reported DMSO solubility. Dissolve the crystalline material completely, inspect for particles, aliquot to minimize freeze-thaw cycles, and add the stock to assay buffer only after dilution planning has been completed.

2. Establish biochemical activity before cellular testing

For an MGL screen, use 4-NPA hydrolysis as a chromogenic starting assay and include a no-enzyme blank, enzyme-plus-vehicle control, and compound-only optical blank. Test a broad concentration series around the reported 0.5 μM benchmark, then fit a four-parameter concentration-response curve under fixed enzyme, substrate, temperature, and incubation conditions. For HSL, use a validated neutral-lipid or ester substrate assay and monitor free fatty acid, glycerol, or another preselected product. Do not compare IC50 values across assays without recording substrate concentration and enzyme loading.

3. Translate the perturbation into an EV-monocyte experiment

Use a factorial design containing untreated cells, EV or liposomal vesicles alone, CAY10499 alone, and combined EV or vesicle plus CAY10499 conditions. Normalize EV input using one consistent metric, such as particle number or total vesicle protein, across all wells. Collect an early sample for lipid mediator changes and a later sample for macrophage-state and checkpoint measurements. Include a viability assay because a reduction in immunosuppressive markers caused by cell loss is not evidence of pathway-specific activity.

4. Add orthogonal readouts

In monocyte-derived macrophage models, pair HSL or MGL activity measurements with targeted lipid analysis for 2-AG, anandamide, free fatty acids, and palmitate where technically available. Assess checkpoint proteins and macrophage markers by the same platform across all conditions. Genetic knockdown or a second chemically distinct perturbation can strengthen target attribution, while ACLY-directed conditions should remain clearly labeled as upstream comparators rather than substitutes for CAY10499.

Protocol Parameters

• Stock preparation: Prepare a 10 mM CAY10499 stock in DMSO, equivalent to 3.553 mg/mL, dispense 20–50 μL aliquots, and store at −20°C for short-term use.
• Biochemical concentration range: Begin with 0.003–30 μM final CAY10499 in a 100 μL assay volume, using a 30 min preincubation at 37°C and a matched vehicle concentration of no more than 0.1% v/v DMSO.
• Cell-based pilot: Screen 0.03, 0.3, and 3 μM CAY10499 for 24 and 48 h, with an untreated control and a 0.1% v/v DMSO vehicle control at every time point.
• Response sampling: Reserve one plate or aliquot at 2–6 h for early lipid changes and a second at 24–48 h for checkpoint, differentiation, and viability measurements.
• Serial dilution: Make at least 8 concentration points with a 3-fold dilution factor for initial IC50 fitting, then repeat the curve with 3 independent enzyme preparations or cell experiments.

The concentrations and time points above are practical starting conditions for optimization, not values reported as a completed CAY10499 protocol in the reference study. The study directly supports the ACLY–palmitate–TAM model; CAY10499 is an experimentally useful downstream probe for testing whether lipase-regulated lipid handling participates in that model.

Advanced applications and comparative advantages

In metabolic disease research, HSL inhibition can help test whether fatty-acid mobilization or cholesterol-ester hydrolysis contributes to a phenotype. This supports use of CAY10499 as a research tool for atherosclerosis, particularly in foam-cell experiments where lipid storage, cholesterol efflux, inflammatory signaling, and viability should be measured together. In adipocyte or adipose-tissue models, pair the compound with glycerol and non-esterified fatty-acid measurements rather than relying on morphology alone.

For endocannabinoid studies, MGL activity can be connected to 2-AG abundance and downstream immune-cell behavior. However, because CAY10499 also inhibits FAAH in the reported recombinant assay, an apparent change in anandamide or 2-AG signaling should be interpreted with both enzyme activities in mind. This multi-enzyme profile is an advantage for mapping coupled lipid metabolism, but a limitation if the objective is to assign a phenotype exclusively to HSL.

The compound also offers a useful contrast between biochemical potency and cellular efficacy. A nanomolar recombinant-enzyme IC50 does not guarantee nanomolar activity in cells because of protein binding, membrane partitioning, uptake, efflux, intracellular metabolism, or substrate competition. Comparing enzyme activity, intracellular lipid concentrations, and cell viability at matched exposure levels provides a more defensible estimate of target engagement.

Why this cross-domain matters, maturity, and limitations

The bridge from EV-transferred ACLY in HCC to CAY10499-controlled lipase activity is mechanistically plausible but experimentally immature. The reference study demonstrates that ACLY cargo in tumor-derived vesicles can drive monocyte-to-TAM reprogramming and that ACLY inhibition in targeted vesicles can reduce immunosuppressive activity. It does not establish that HSL, MGL, or FAAH is required for that response, nor does it test CAY10499. Accordingly, CAY10499 should be used to generate a downstream lipid-handling hypothesis, not to reproduce the reported ACLY mechanism.

Strong conclusions require matched EV input, vehicle controls, viability data, quantitative lipid measurements, and an upstream ACLY comparator. The minimal CB1 and CB2 displacement reported for the compound is helpful, but it does not eliminate all off-target or context-dependent effects. These limitations are especially important in primary monocytes, macrophages, and tumor co-cultures, where metabolic state can vary substantially between donors and passages.

Troubleshooting and optimization tips

Precipitation or inconsistent dosing

Because CAY10499 is water-insoluble, direct addition of concentrated stock to aqueous media can create transient precipitation and uneven exposure. Pre-dilute into a compatible intermediate solution, add slowly while mixing, and inspect the final working solution. Keep the vehicle identical across all wells and use compound-only blanks in optical assays.

Unexpectedly weak inhibition

Check whether the enzyme assay is operating in a substrate-saturated range, whether the protein concentration is excessive, and whether incubation remains within the linear product-formation window. An IC50 measured with 4-NPA should not be expected to match an HSL assay using a triglyceride or cholesterol ester substrate. Rebuild the concentration-response curve after confirming enzyme activity in the vehicle control.

High variability in 4-NPA or lipid readouts

Use edge-well controls or a humidified plate environment, randomize treatment positions, and confirm that absorbance remains linear over the selected reading interval. Compound-only wells are essential because colored or light-scattering precipitates can mimic enzymatic signal. For lipidomics, process samples in randomized batches and include pooled quality-control material.

Cell toxicity or apparent macrophage reprogramming

Measure viability at each CAY10499 concentration and time point, especially when combining the compound with EVs or liposomal vesicles. If the phenotype appears only at the highest dose, repeat with lower exposure and a shorter pretreatment. A loss of TAM-associated markers without preserved cell number should be reported as cytotoxic or nonspecific unless target engagement is independently demonstrated.

Loss of potency during storage

Store the solid at −20°C, protect prepared solutions from repeated thawing, and use solutions for short-term experiments. If potency drifts, compare a fresh aliquot with the older solution in the same enzyme plate. Avoid making a large aqueous master mix because the compound is not water-soluble.

Future outlook

The most informative next step is a layered comparison of ACLY-directed and lipase-directed perturbations in the CD81-vesicle or EV-monocyte system described by the reference study. Measuring palmitate synthesis, 2-AG and anandamide handling, checkpoint stability, macrophage state, and viability together could clarify whether downstream lipid mobilization modifies the ACLY-driven phenotype. Combination experiments with the anti-PD-1 or anti-PD-L1 context already discussed in the study may further define whether metabolic rewiring influences immunotherapy response. Until such experiments are completed, CAY10499 should remain a research-only mechanistic tool and not a diagnostic or medical treatment.